Zenas BioPharma Inc.
ZBIO | NASDAQ
$25.93
-$2.53 (-8.89%)
At close: Nov 5, 2026, 4:00 PM ET
$24.00
-$1.93 (-7.44%)
After-hours:
Nov 5, 2026, 5:53 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
Net Income | -377.74M | -156.99M | -37.12M | -119.28M |
Depreciation & Amortization | -1.88M | 137K | 113K | 78K |
Stock-Based Compensation | 26.35M | 10.82M | 3.5M | 737K |
Other Working Capital | 10.99M | 13.69M | -7.62M | 6.88M |
Other Non-Cash Items | 179.98M | 925K | 11.03M | 44.85M |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | 951K | 25.43M | -8.04M | 7.97M |
Operating Cash Flow | -172.33M | -119.67M | -30.53M | -65.65M |
Capital Expenditures | -18K | -131K | -17K | -2.2M |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | -417.76M | -36.42M | n/a | n/a |
Sales Maturities Of Investments | 200.89M | 6M | n/a | n/a |
Other Investing Acitivies | -35M | n/a | n/a | -2M |
Investing Cash Flow | -251.89M | -30.55M | -17K | -2.2M |
Debt Repayment | n/a | n/a | 20M | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 62.34M | -6.06M | n/a | n/a |
Financial Cash Flow | 215.28M | 412.96M | 20.12M | 59.39M |
Net Cash Flow | -209.19M | 262.89M | -10.35M | -8.5M |
Free Cash Flow | -172.35M | -119.81M | -30.55M | -67.85M |
Adj. Free Cash Flow | -198.7M | -130.63M | -34.04M | -68.59M |
Maintenance CapEx | n/a | -131K | n/a | -78K |
Growth CapEx | -18K | n/a | -17K | -2.12M |
Owner Earnings | -172.33M | -119.81M | -30.53M | -65.73M |
Add to Watchlist
Select watchlists to add or remove ZBIO